Massive Bio has entered a partnership with OpenAI to expand global access to clinical studies through AI-driven parameterisation of protocols and real-time patient pre-screening.
The collaboration forms part of OpenAI’s Impact Hours programme, which supports initiatives focused on benefiting large populations worldwide.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Through working with OpenAI, Massive Bio has gained the ability to convert complex clinical trial criteria from sponsors and public registries into machine-readable formats suitable for pre-screening services.
The transformation enables immediate and automated patient pre-screening against ongoing trials, reducing the time required to match eligible patients and lessening the associated operational workload.
This resulting scalable pre-screening infrastructure now supports broader access to clinical trials across oncology and haematology.
By shifting from manual eligibility interpretation to automated parameterisation and matching, Massive Bio can swiftly identify eligible patients, enhance referral and enrolment efficiency, and reach larger global patient populations.
As part of this collaboration, the company will provide free pre-screening services in selected regions, aiming to remove barriers to clinical trial access and support health equity efforts.
OpenAI recently introduced ChatGPT for Clinicians, providing verified individual clinicians in the US with free access to advanced AI tools supporting clinical workflows, trusted search, and research tools.
Massive Bio chief medical AI officer Arturo Loaiza-Bonilla said: “Clinical trials have historically been limited by accessibility and operational complexity.
“By collaborating with OpenAI, we are transforming how trials are interpreted and operationalised, making pre-screening faster, more scalable, and significantly more accessible to patients worldwide.
“This collaboration enables us to move from static, manually curated eligibility criteria toward a dynamic, AI-driven parameterisation layer that continuously aligns patients with the right trials in real time. It is exactly the kind of infrastructure-level deployment that can close the gap between the thousands of open trials and the millions of patients who never learn they may qualify.”
In September 2024, Massive Bio launched Patient Connect, a free portal that aims to personalise access to cancer clinical trials worldwide.
